专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130165522A1 GEL FORMULATIONS FOR THE TOPICAL USE OF 1-AMINO-ALKYLCYCLOHEXANE DERIVATIVES 审中-公开
标题翻译： 1-氨基 - 甲基环己烷衍生物的局部使用凝胶制剂
公开(公告)号：US20130165522A1
公开(公告)日：2013-06-27
申请号：US13704065
申请日：2011-06-17
申请人： Petra Scheppler , Bernhard Hauptmeier , Alexander Linko , Harry Abts
发明人： Petra Scheppler , Bernhard Hauptmeier , Alexander Linko , Harry Abts
IPC分类号： A61K31/13
CPC分类号： A61K31/13 , A61K9/0014 , A61K9/06 , A61K47/36 , A61K47/38
摘要： This invention provides a pharmaceutical composition for topical application to the skin of a patient in need of, comprising neramexane or a pharmaceutically acceptable salt thereof, and at least one gel forming agent for the treatment or prevention of inflammatory skin diseases such as impetigo contagiosa, acne, rosacea, eczema, atopic dermatitis, contact dermatitis, seborrheic dermatitis, psoriasis, and/or oily skin. The at least one gel forming agent comprises polymers with neutral and/or positively charged polymer backbones.
摘要翻译：本发明提供了一种用于局部应用于需要包含奈拉美生或其药学上可接受的盐的患者皮肤的药物组合物，以及至少一种用于治疗或预防炎性皮肤疾病如脓疱病，痤疮的凝胶形成剂，红斑痤疮，湿疹，特应性皮炎，接触性皮炎，脂溢性皮炎，牛皮癣和/或油性皮肤。至少一种凝胶形成剂包含具有中性和/或带正电荷的聚合物主链的聚合物。

2. 发明申请

US20130143869A1 USE OF A CATIONIC AMPHIPHILIC DRUG FOR THE PREPARATION OF A FORMULATION FOR THE REDUCTION OF SUBCUTANEOUS ADIPOSE TISSUE 审中-公开
标题翻译：用于制备用于减少扁桃体组织的制剂的阳离子药代动力学
公开(公告)号：US20130143869A1
公开(公告)日：2013-06-06
申请号：US13810337
申请日：2011-07-14
申请人： Kevin Kiehm , Bernhard Hauptmeier , Harry Abts , Peter Boderke
发明人： Kevin Kiehm , Bernhard Hauptmeier , Harry Abts , Peter Boderke
IPC分类号： A61K31/55 , A61K31/135 , A61K31/164 , A61K31/4706 , A61K31/343
CPC分类号： A61K31/55 , A61K8/42 , A61K8/49 , A61K8/4926 , A61K8/63 , A61K8/69 , A61K31/135 , A61K31/137 , A61K31/138 , A61K31/164 , A61K31/335 , A61K31/343 , A61K31/357 , A61K31/435 , A61K31/4406 , A61K31/454 , A61K31/4545 , A61K31/4706 , A61K31/5415 , A61K31/551 , A61K31/5513 , A61K31/609 , A61K45/06 , A61K2800/91 , A61Q19/06
摘要： Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction and/or prevention of subcutaneous adipose tissue with improved effectiveness and better reproducible activity.
摘要翻译：使用阳离子两亲药物制备用于减少和/或预防皮下脂肪组织的制剂，具有改善的有效性和更好的可再生活性。

3. 发明申请

US20110236439A1 Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane 有权
标题翻译： 1-氨基环己烷化合物，美金刚和neramexane的即时释放配方
公开(公告)号：US20110236439A1
公开(公告)日：2011-09-29
申请号：US13134467
申请日：2011-06-08
申请人： Yan Yang , Rajiv Janjikhel , Niranjan Rao , Antonia Periclou , Wattanaporn Abramowitz , Mahendra G. Dedhiya , Erhard Seiller , Bernhard Hauptmeier
发明人： Yan Yang , Rajiv Janjikhel , Niranjan Rao , Antonia Periclou , Wattanaporn Abramowitz , Mahendra G. Dedhiya , Erhard Seiller , Bernhard Hauptmeier
IPC分类号： A61K9/00 , A61K31/13 , A61K31/205 , A61P25/28 , A61P25/16 , A61P25/04 , A61P25/08 , A61P27/06 , A61P25/24 , A61P31/14 , A61P33/06 , A61P1/16 , A61P25/00
CPC分类号： A61K31/13 , A61K9/28 , A61K9/2846 , A61K9/2866 , A61K47/38 , Y02A50/411
摘要： The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.
摘要翻译：本发明涉及含有1-氨基环己烷，优选美金刚或奈拉美生和任选的药学上可接受的包衣的立即释放的固体口服剂型，其中活性成分表现出剂量比例，并以大于约80％的溶解速率释放大约在所述表格进入使用环境后的前60分钟。剂型是直接压制的并且硬度在约3至约40Kp之间的范围内，平均Tmax在约2至约8小时的范围内，活性成分负载在约2.5至约150的范围内 mg。该制剂允许剂量比例组合物每天一次或b.i.d。同时保持Tmax的稳定平均范围。

4. 发明申请

US20060002999A1 Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane 审中-公开
公开(公告)号：US20060002999A1
公开(公告)日：2006-01-05
申请号：US11155319
申请日：2005-06-16
申请人： Yan Yang , Rajiv Janjikhel , Niranjan Rao , Antonia Periclou , Wattanaporn Abramowitz , Mahendra Dedhiya , Erhard Seiller , Bernhard Hauptmeier
发明人： Yan Yang , Rajiv Janjikhel , Niranjan Rao , Antonia Periclou , Wattanaporn Abramowitz , Mahendra Dedhiya , Erhard Seiller , Bernhard Hauptmeier
IPC分类号： A61K9/20 , A61K31/13
CPC分类号： A61K31/13 , A61K9/28 , A61K9/2846 , A61K9/2866 , A61K47/38 , Y02A50/411
摘要： The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.

5. 发明申请

US20120283274A1 CRYSTALLINE FORMS OF SUBSTITUTED PYRAZOLOPYRIMIDINES 审中-公开
标题翻译：取代的吡唑并嘧啶的晶体形式
公开(公告)号：US20120283274A1
公开(公告)日：2012-11-08
申请号：US13508404
申请日：2010-11-24
申请人： Patrick Plitt , Bernhard Hauptmeier , Peter Boderke
发明人： Patrick Plitt , Bernhard Hauptmeier , Peter Boderke
IPC分类号： A61K31/519 , A61P25/28 , A61P25/18 , C07D471/04
CPC分类号： C07D487/04
摘要： The present invention relates to novel co-crystals of pyrazolopyrimidines and a co-crystal former, wherein the co-crystal former is an organic carboxylic acid, preferably selected from the group of gentisic acid, succinic acid and xinafoic acid.
摘要翻译：本发明涉及吡唑并嘧啶和共结晶形成剂的新型共晶体，其中共晶形成剂是有机羧酸，优选选自龙胆酸，琥珀酸和嘧啶酸。

6. 发明申请

US20140178512A1 IN SITU FORMATION OF A FILLER 审中-公开
标题翻译：填充填料的形成
公开(公告)号：US20140178512A1
公开(公告)日：2014-06-26
申请号：US14000480
申请日：2012-02-17
申请人： Kevin Kiehm , Bernhard Hauptmeier , Peter Boderke
发明人： Kevin Kiehm , Bernhard Hauptmeier , Peter Boderke
IPC分类号： A61L27/20
CPC分类号： A61L27/20 , A61L31/042 , C08L5/06 , C08L5/00
摘要： The present invention pertains to a method for the in situ preparation of a filler, comprising the step of applying a polyanionic biopolymer solution at an application site below the dermis of a patient for restoring volume at said application site, wherein the polyanionic biopolymer is selected from pectin and gellan. Furthermore, the present invention pertains to a kit comprising (i) a polyanionic biopolymer solution; and (ii) a solution comprising at least one divalent cation.
摘要翻译：本发明涉及一种原位制备填料的方法，其包括以下步骤：将聚阴离子生物聚合物溶液施用于患者真皮下方的应用部位，以恢复所述施用部位的体积，其中所述聚阴离子生物聚合物选自果胶和结冷胶。此外，本发明涉及一种试剂盒，其包含（i）聚阴离子生物聚合物溶液; 和（ii）包含至少一种二价阳离子的溶液。

7. 发明申请

US20130142870A1 NERAMEXANE MULTIPLE UNIT DOSAGE FORM 有权
标题翻译： NERAMEXANE多单元剂型
公开(公告)号：US20130142870A1
公开(公告)日：2013-06-06
申请号：US13806255
申请日：2011-06-22
申请人： Bernhard Hauptmeier , Brigitte Purmann
发明人： Bernhard Hauptmeier , Brigitte Purmann
IPC分类号： A61K9/48 , A61K31/13 , A61K9/28
CPC分类号： A61K31/13 , A61K9/2027 , A61K9/2846 , A61K9/5026 , A61K9/5078 , Y02A50/411
摘要： Unit comprising neramexane, a pharmaceutically acceptable salt, solvate, conjugate, prodrug, polymorphic form, isomer, or derivative thereof; and a release-controlling excipient; wherein said unit has a diameter of from 0.1 to less than 6 mm.
摘要翻译：包含奈拉美生，其药学上可接受的盐，溶剂合物，缀合物，前药，多晶型物，异构体或其衍生物的单元; 和释放控制赋形剂; 其中所述单元的直径为0.1至小于6mm。

8. 发明授权

US08394857B2 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases 失效
标题翻译： 1-氨基 - 烷基环己烷衍生物，用于治疗炎性皮肤病
公开(公告)号：US08394857B2
公开(公告)日：2013-03-12
申请号：US12653865
申请日：2009-12-18
申请人： Peter Boderke , Alexander Gebauer , Bhushan Hardas , Bernhard Hauptmeier , Rainer Pooth
发明人： Peter Boderke , Alexander Gebauer , Bhushan Hardas , Bernhard Hauptmeier , Rainer Pooth
IPC分类号： A61K31/13
CPC分类号： A61K31/13 , A61K9/0014 , A61K9/06 , A61K9/2054 , A61K45/06 , A61K2300/00
摘要： The present invention relates to the treatment of an individual afflicted with inflammatory skin diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.
摘要翻译：本发明涉及治疗患有炎性皮肤疾病的个体，包括给予个体有效量的1-氨基 - 烷基环己烷衍生物。

9. 发明申请

US20070141148A1 Neramexane MR matrix tablet 审中-公开
标题翻译： Neramexane MR矩阵片
公开(公告)号：US20070141148A1
公开(公告)日：2007-06-21
申请号：US11604986
申请日：2006-11-27
申请人： Bernhard Hauptmeier , Andreas Becker
发明人： Bernhard Hauptmeier , Andreas Becker
IPC分类号： A61K9/22 , A61K31/13
CPC分类号： A61K9/2054 , A61K9/2866 , A61K31/13
摘要： The invention provides novel oral modified release dosage forms of neramexane which are useful for the continuous therapy of patients suffering from diseases and conditions such as Alzheimer's dementia and neuropathic pain. The compositions have drug release profiles that are suitable for achieving steady state plasma concentrations of neramexane which have relatively small fluctuation when administered on a twice-daily or even once-daily regimen. The dosage forms may be designed as modified release matrix tablets, which are optionally coated for taste masking. The invention further provides therapeutic methods of treating conditions such as Alzheimer's dementia and neuropathic pain which involve the administration of such dosage forms.
摘要翻译：本发明提供了奈拉美生的新型口服调释剂型，其可用于持续治疗患有诸如阿尔茨海默氏痴呆和神经性疼痛的疾病和病症的患者。组合物具有药物释放曲线，其适用于在以每日两次甚至每日一次的方案施用时实现具有相对较小波动的稳定状态的奈拉美生血浆浓度。剂型可以设计为改性释放基质片剂，其可任选地包被以掩盖味道。本发明进一步提供了治疗诸如阿尔茨海默氏痴呆和神经性疼痛的疾病的治疗方法，其涉及这种剂型的施用。

10. 发明申请

US20130090306A1 CHITOSAN BEADS AND FILLER COMPRISING SUCH BEADS 有权
标题翻译： CHITOSAN珠和包装这种珠子的填料
公开(公告)号：US20130090306A1
公开(公告)日：2013-04-11
申请号：US13639004
申请日：2011-04-07
申请人： Kevin Kiehm , Bernhard Hauptmeier , Peter Boderke
发明人： Kevin Kiehm , Bernhard Hauptmeier , Peter Boderke
IPC分类号： A61L27/20
CPC分类号： A61K8/0204 , A61K8/025 , A61K8/365 , A61K8/735 , A61K8/736 , A61K9/1652 , A61K31/167 , A61K2800/30 , A61K2800/54 , A61K2800/56 , A61K2800/654 , A61K2800/72 , A61L27/20 , A61L31/042 , A61Q19/08 , Y10T428/2982 , C08L5/08
摘要： The present invention pertains to chitosan beads consisting of chitosan cross-linked with citrate ions. The present invention furthermore pertains to a filler comprising such chitosan-citrate beads. In one embodiment of the instant invention the filler is a dermal filler. In one further embodiment of the present invention the dermal filler is for the treatment of wrinkles and/or folds. In another embodiment of the instant invention the filler is for use in the treatment of a medical condition. The filler provided in the present invention may further comprise one or more active pharmaceutical ingredients. Further, the present invention pertains to a process for preparing the filler as claimed herein.
摘要翻译：本发明涉及由与柠檬酸根离子交联的壳聚糖组成的壳聚糖珠粒。本发明还涉及包含这种壳聚糖 - 柠檬酸盐珠粒的填料。在本发明的一个实施方案中，填料是真皮填料。在本发明的另一个实施方案中，真皮填料用于治疗皱纹和/或折痕。在本发明的另一个实施方案中，所述填料用于治疗疾病。本发明中提供的填料还可以包含一种或多种活性药物成分。此外，本发明涉及制备本文所要求的填料的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式